Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?
HIV
hepatitis B vaccination
practice patterns
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
13
06
2023
received:
13
01
2023
accepted:
16
06
2023
medline:
20
9
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.
Substances chimiques
Hepatitis B Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
790-792Informations de copyright
© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Références
Johnson TM, Klepser DG, Bares SH, Scarsi KK. Predictors of vaccination rates in people living with HIV followed at a specialty care clinic. Hum Vaccin Immunother. 2021;17(3):791-796. doi:10.1080/21645515.2020.1802163
Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355. doi:10.1093/jnci/djp288
El-Serag HB, Sardell R, Thrift AP, Kanwal F, Miller P. Texas has the highest hepatocellular carcinoma incidence rates in the USA. Dig Dis Sci. 2021;66(3):912-916. doi:10.1007/s10620-020-06231-4
Weiser J, Perez A, Bradley H, King H, Shouse RL. Low prevalence of hepatitis B vaccination among patients receiving medical care for HIV infection in the United States, 2009 to 2012. Ann Intern Med. 2018;168(4):245-254. doi:10.7326/M17-1689
Tian Y, Hua W, Wu Y, et al. Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis. Front Immunol. 2021;12:745541. doi:10.3389/fimmu.2021.745541
Kim HN, Newcomb CW, Carbonari DM, et al. Risk of HCC with hepatitis B viremia among HIV/HBV-coinfected persons in North America. Hepatology. 2021;74(3):1190-1202. doi:10.1002/hep.31839
Boettiger DC, Khol V, Durier N, Law M, Sun LP. HIV viral suppression in TREAT Asia HIV observational database enrolled adults on antiretroviral therapy at the social health clinic, the National Center for HIV/AIDS, dermatology & STDs, Phnom Penh, Cambodia. Antivir Ther. 2016;21(8):725-730. doi:10.3851/IMP3052
Marks KM, Kang M, Umbleja T, et al. Immunogenicity and safety of hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HEPLISAV-B) in HBV vaccine-naive people with HIV. Clin Infect Dis. 2023:ciad201. doi:10.1093/cid/ciad201